Univeristätsklinikum Essen
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hüttmann, Andreas
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
Hanoun, Maher
INITIAL-1, NCT03460522 / 2016-004836-39: Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Recruiting
2
65
Europe
Inotuzumab ozogamicin
Nicola Goekbuget, Pfizer Pharma GmbH
Precursor Cell Lymphoblastic Leukemia
06/25
12/25
VINCENT, NCT05904106 / 2021-003248-26: Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

Recruiting
2
146
Europe
Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin
Technische Universität Dresden, University Hospital Heidelberg, AbbVie
Acute Myeloid Leukemia
09/28
09/28
GMALL-BLIVEN, NCT05182385: Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Recruiting
1/2
39
Europe
Blinatumomab, blincyto, Venetoclax, Venclyxto
Goethe University, University Hospital Schleswig-Holstein
ALL, Recurrent, Adult
06/25
12/25
RELAX, NCT04330820 / 2018-003025-28: Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax

Active, not recruiting
1/2
55
Europe
Venetoclax Oral Tablet, Cytarabin
Technische Universität Dresden, AbbVie
Relapsed Adult AML, Refractory AML
10/23
08/25
MOSAIC, NCT04385290 / 2019-003863-23: Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia

Recruiting
1/2
214
Europe
MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin
Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer
Acute Myeloid Leukemia
04/27
04/28
NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

Recruiting
N/A
15000
Europe
Technische Universität Dresden
Acute Myeloid Leukemia (AML)
09/30
09/30

Download Options